Sigilon Therapeutics Is A Biopharmaceutical Company Dedicated To Developing Functional Cures For A Variety Of Acute And Chronic Diseasesacquired By Eli Lilly And Company In 2023Sigilon Enhances Its Capabilities In Cell And Gene Therapy The Company Utilizes Its Shielded Living Therapeuticssltxplatformwhich Combines Differentiated Stem Cells And Proprietary Biocompatible Spheresthis Innovative Approach Allows For The Creation Of Specific Cell Types For Therapeutic Programssuch As Insulin Secreting Cells For Type 1 Diabetessigilon S Lead Product Candidatesig 002Aims To Replace Islet Cells In T1D Treatmentwhile The Company Is Also Exploring Therapies For Lysosomal Diseases And Other Conditions With A Workforce Of Around 62 Employeessigilon Operates In The Biotechnology And Medical Research Sectorfocusing On Advancing Therapeutic Treatments For Chronic Diseasesthe Partnership With Eli Lilly Is Expected To Expand Sigilon S Resources And Reach In Developing These Important Therapies
